The First Information- and AI-Driven Gerotherapeutics Aimed at an Aging-Specific Target
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
While traditional pharmaceuticals act by binding to single, specific receptor to affect a regulatory pathway, modifying biological function, MitoXcel™ Technology introduces a revolutionary new class of peptide therapeutics whose effects are determined by the biophysical properties created by their amino acid sequences—much like DNA conveys genetic instructions through its nucleotide sequence. Instead of relying on a single, defined chemical entity, MitoXcel™ Technology is a powerful family of peptides—each precisely engineered to meet a unique set of design rules based on their amino acid sequences. Only those that match the MitoXcel™ blueprint qualify, ensuring consistent performance at the molecular level. Thus, MitoXcel™ peptides are the first ever information-based gerotherapeutics, specifically engineered to target the age-related decline in Mitochondrial Membrane Potential (Δψm) observed across all living organisms. By addressing this decline, MitoXcel™ reverses aging-related changes through two distinct mitochondrial-mediated mechanisms of action. These two mechanisms include Mechanism 1, the return of the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and Mechanism 2, which steadily and profoundly eliminates senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects, with no apparent adverse side
GEROTHERAPEUTIX is actively growing a database of newly generated candidate MitoXcel geropeptides, that are then tested in a proprietary set of in vitro assays to assess their potencies for Mechanism 1 and 2. Through an iterative learning process, MitoXcelAI™—the platform’s proprietary artificial intelligence engine—analyzes this growing dataset to train and refine predictive algorithms. This continuous feedback loop enhances the design rules that define MitoXcel™ Technology, much like the iPhone periodically updates its operating system, ensuring its evolution as a best-in-class, information-engineered solution for generating novel geropeptides that combat age-related decline.
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc., which was registered in Texas as d/b/a GEROTHERAPEUTIX, Inc. in 2025: (1) Eos SENOLYTIX, a longevity company developing novel MitoXcel™ geropeptide therapeutics to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel MitoXcel™ oncopeptides to treat cancer via this same novel target as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them, and our MitoXcel™ Technology website, that explains the remarkable technology driving them!
Eos SENOLYTIX’s PTC-2105, PTC-2107, and PTC-2113, Perseus SENOLYTIX’s PTC-2109, PTC-2110, PTC-2117 and PTC-2128 and Ponce Aurora’s PTC-2111, PTC-2116. PTC-2119 and PTC-2132 are all powered by MitoXcel™ Technology
Eos SENOLYTIX™, Perseus SENOLYTIX™, Phoenix SENOLYTIX™ and Ponce Aurora™ are affiliates of GEROTHERAPEUTIX™, Inc. Visit our affiliate Companies to learn more about them!
